Xcelthera Inc

Xcelthera is founded to leverage stem cell therapy and regenerative medicine development and manufacturing innovations to provide the next generation of cell-based therapeutic solutions for unmet medical needs in world-wide major health problems. The Company is a major innovator in the stem cell research and regenerative medicine market, and uniquely holds the key breakthrough technologies/patents/IP/rights for the major bottlenecks in the regenerative medicine market, including large-scale production of high quality clinical-grade pluripotent human embryonic stem cell (hESC) lines and their functional human neuronal and heart cell therapy products for commercial and therapeutic uses (USPTO patent # 9,428,731; # 8,716,017). Stem Cell Technology: The Company’s PluriXcel human stem cell technology provides proprietary clinical-grade translating capabilities to address key challenges to traditional medicine & biofabrication, and offers currently the only available human cell sources in large quantity and high quality with adequate cellular capacity to regenerate the contractile heart muscle and the neuron circuitry, overcoming major bottlenecks for tissue repair & biofabrication, including: PluriXcel-DCS (defined culture system) Platform; PluriXcel-SMI (small molecule induction)-Heart Platform; PluriXcel-SMI-Neuron Platform. Stem Cell Product: The Company’s Xcel cell therapy product prototypes provide the only available human cell sources in commercial scales with adequate cellular pharmacologic utility and capacity to regenerate the neurons and contractile heart muscles, vital for neurological and heart repair for a wide range of incurable or hitherto untreatable neurological and cardiovascular diseases in the clinical setting, including: Xcel-hNuP, Xcel-hNu, Xcel-hCardP, Xcel-hCM.